Cargando…
The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer
AIMS: To assess whether the exposure–response relation for abiraterone is different in pre‐chemotherapy patients compared to post‐chemotherapy patients with metastatic castration‐resistant prostate cancer (mCRPC). METHODS: Data were collected from three clinical studies in mCRPC patients treated wit...
Autores principales: | Boerrigter, Emmy, Benoist, Guillemette E., Overbeek, Joanneke K., Donders, Rogier, Mehra, Niven, van Oort, Inge M., ter Heine, Rob, van Erp, Nielka P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293353/ https://www.ncbi.nlm.nih.gov/pubmed/34436788 http://dx.doi.org/10.1111/bcp.15057 |
Ejemplares similares
-
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment
por: Boerrigter, Emmy, et al.
Publicado: (2021) -
A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics
por: Lubberman, Floor J. E., et al.
Publicado: (2019) -
The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients
por: Benoist, Guillemette E., et al.
Publicado: (2020) -
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
por: Benoist, Guillemette E., et al.
Publicado: (2016) -
Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide
por: Podgoršek, Eva, et al.
Publicado: (2023)